Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Fluorodeoxyglucose (FDG) is a radiopharmaceutical used in positron emission tomography (PET) imaging. It is an analog of glucose where one hydroxyl group is replaced by the radionuclide fluorine-18. FDG is used to visualize tissues with high glucose uptake, such as tumors, areas of inflammation, and metabolically active brain regions. It is the most commonly used PET tracer.
FDG is taken up by cells similarly to glucose but is trapped intracellularly after phosphorylation by hexokinase. The accumulation of FDG reflects the glucose metabolic activity of the tissue. The 18F isotope emits positrons, which are detected by PET scanners to create images of FDG distribution.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Fluorodeoxyglucose (FDG).